National Kidney Foundation Innovation Fund Invests In Revalia Bio To Advance Innovative Kidney Disease Therapeutics  

The National Kidney Foundation (NKF) Innovation Fund recently invested in Revalia Bio, which is focused on developing and delivering personalized care for consumers with kidney disease.;The investment amount was not disclosed. ;

Revalia Bio’s technology is focused on use of human organs donated for research. The organs are revived with advanced organ perfusion methods, which allows the researchers to study the organs in a near-living state and generate data that offers insight into human biology and disease.;

The company will use the NKF investment to accelerate its efforts to improve the future of care for . . .